CagriSema trial analysis finds 25% weight loss in women

Novo Nordisk’s experimental CagriSema, which combines semaglutide and cagrilintide, was associated with an average 25% weight loss among women over 68 weeks in a post-study analysis of late-stage trial data, compared with about 3% for placebo. Weight loss was reported across premenopausal, perimenopausal and postmenopausal groups, though the analysis assumed participants stayed on treatment throughout. Separately, a meta-analysis of six trials in people with type 2 diabetes found improvements in blood sugar, weight, waist circumference and systolic blood pressure, with benefits and gastrointestinal side effects varying by dose. The findings add to interest in combining appetite- and glucose-regulating pathways, but CagriSema remains experimental.